Author, as appears in the article.: Ettcheto M; Sánchez-Lopez E; Cano A; Carrasco M; Herrera K; Manzine PR; Espinosa-Jimenez T; Busquets O; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A
Department: Bioquímica i Biotecnologia
URV's Author/s: Folch Lopez, Jaume
Keywords: Western blotting Unfolded protein response Synapsis Risk factor Polymerase chain reaction Nonhuman Neuroinflammation Nervous system inflammation Mouse Metabolic alterations Liver Lipid diet Insulin tolerance test In vivo study Hippocampus High fat diet Glucose tolerance test Glucose tolerance Female Dexibuprofen Controlled study Cognitive deficits Chromosome pairing Body weight Article Appswe/ps1de9 Animal model Animal experiment Amyloid plaque Amyloid beta protein Alzheimer´s disease Alzheimer disease Adult ?a plaques
Abstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´s disease (AD) where inflammation plays a pivotal role. However, mechanisms involved still remain unclear. In the present study, we aimed to evaluate central and peripheral effects of dexibuprofen (DXI) in the progression of AD in APPswe/PS1dE9 (APP/PS1) female mice, a familial AD model, fed with high fat diet (HFD). Animals were fed either with conventional chow or with HFD, from their weaning until their sacrifice, at 6 months. Moreover, mice were divided into subgroups to which were administered drinking water or water supplemented with DXI (20 mg kg?1 d?1) for 3 months. Before sacrifice, body weight, intraperitoneal glucose and insulin tolerance test (IP-ITT) were performed to evaluate peripheral parameters and also behavioral tests to determine cognitive decline. Moreover, molecular studies such as Western blot and RT-PCR were carried out in liver to confirm metabolic effects and in hippocampus to analyze several pathways considered hallmarks in AD. Results: Our studies demonstrate that DXI improved metabolic alterations observed in transgenic animals fed with HFD in vivo, data in accordance with those obtained at molecular level. Moreover, an improvement of cognitive decline and neuroinflammation among other alterations associated with AD were observed such as beta-amyloid plaque accumulation and unfolded protein response. Conclusions: Collectively, evidence suggest that chronic administration of DXI prevents the progression of AD through the regulation of inflammation which contribute to improve hallmarks of this pathology. Thus, this compound could constitute a novel therapeutic approach in the treatment of AD in a combined therapy. © 2021, The Author(s).
Thematic Areas: Medicina ii General biochemistry,genetics and molecular biology Biochemistry, genetics and molecular biology (miscellaneous) Biochemistry, genetics and molecular biology (all) Biochemistry & molecular biology
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: jaume.folch@urv.cat
Author identifier: 0000-0002-5051-8858
Record's date: 2024-07-27
Papper version: info:eu-repo/semantics/publishedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Cell And Bioscience. 11 (1):
APA: Ettcheto M; Sánchez-Lopez E; Cano A; Carrasco M; Herrera K; Manzine PR; Espinosa-Jimenez T; Busquets O; Verdaguer E; Olloquequi J; Auladell C; Folch J (2021). Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice. Cell And Bioscience, 11(1), -. DOI: 10.1186/s13578-021-00646-w
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV